Last updated: 11/07/2018 08:36:29

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic obstructive pulmonary disease (COPD) Patients

Request patient level data
GSK study ID
115119
See study documents
Clinicaltrials.gov ID
NCT02130635
See results summary
EudraCT ID
2014-000313-31
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A Double-Blind (sponsor unblind), Placebo Controlled, Randomised, Parallel Group Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of GSK2269557 Administered as a Dry Powder to COPD Patients and Assessment of Dose Response using Sputum Biomarkers
Trial description: This is a randomised, double-blind, placebo controlled, parallel group study to evaluate the safety, tolerability, pharmacokinetics and dose response of multiple doses of GSK2269557 administered as a dry powder in COPD subjects. Pharmacodynamic effects on biomarkers will also be assessed. This study will have two parts. In Part A, subjects will be randomized to active or placebo treatment in a 3:1 ratio and in Part B, to placebo or one of the six doses of active treatment in an equal ratio. A sufficient number of COPD subjects (male and female of non-child bearing potential) will be screened to ensure that approximately 30 subjects are enrolled and at least 20 evaluable subjects are obtained for Part A and approximately 35 subjects will be enrolled for Part B. In both the parts, subjects will receive study treatment once daily for 14 consecutive days. Placebo control will be included for a valid evaluation of adverse events attributable to treatment versus those independent of treatment.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:

Part A: Number of participants with at least one non-serious adverse event (AE), serious adverse event (SAE), or drug-related adverse event

Timeframe: From the start of study treatment until follow-up (assessed for approximately 19 days)

Part A: Change from Baseline in counts of white blood cells (WBC), total neutrophils (total absolute neutrophil count [ANC]), lymphocytes, monocytes, eosinophils, basophils, and platelets at the indicated time points

Timeframe: Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)

Part A: Change from Baseline in hemoglobin and mean corpuscle hemoglobin concentration (MCHC) at the indicated time points

Timeframe: Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 h post-dose)

Part A: Change from Baseline in hematocrit at the indicated time points

Timeframe: Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)

Part A: Change from Baseline in counts of RBCs and reticulocytes at the indicated time points

Timeframe: Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)

Part A: Change from Baseline in mean corpuscle hemoglobin (MCH) at the indicated time points

Timeframe: Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)

Part A: Change from Baseline in mean corpuscle volume (MCV) at the indicated time points

Timeframe: Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)

Part A: Change from Baseline in albumin and total protein at the indicated time points

Timeframe: Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)

Part A: Change from Baseline in alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), and gamma glutamyl transferase (GGT) at the indicated time points

Timeframe: Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)

Part A: Change from Baseline in creatinine, bilirubin, and total bilirubin at the indicated time points

Timeframe: Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)

Part A: Change from Baseline in calcium, potassium, sodium, glucose, and blood urea nitrogen (BUN) at the indicated time points

Timeframe: Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)

Part A: Number of participants meeting criteria of potential clinical importance for systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate (HR) at any visit post-Baseline

Timeframe: Day 1, Day 7, and Day 14

Part A: Number of participants with normal and abnormal (clinically significant or not clinically significant) findings in 12-lead electrocardiogram (ECG) at any visit post-Baseline

Timeframe: Day 1, Day 7, and Day 14

Part A: Change from Baseline in forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) at the indicated time points

Timeframe: Baseline (Day 1 [pre-dose]), Day 1 (1 h post-dose), Day 7 (pre-dose and 1 h post-dose), and Day 14 (24 h post-dose)

Part B: Adjusted median response of cytokine (Interleukin 6 [IL6], Interleukin 8 [IL8], Tumor Necrosis Factor alpha [TNFalpha]) concentrations in induced sputum, on Day 7 and Day 14

Timeframe: Day 7 (pre-dose) and Day 14 (24 h post-dose)

Secondary outcomes:

Part A: Day 1 plasma concentration of GSK2269577 up to 6 hours post dose

Timeframe: Day 1 (Pre-dose, 5 min, 30 min, 1, 2, 4 & 6 hours post-dose)

Part B: Day 1 plasma concentration of GSK2269577 up to 6 hours post dose

Timeframe: Pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, and 6 h post-dose on Day 1

Part A: Maximum observed plasma concentration (Cmax) of GSK2269577 on Day 7

Timeframe: Day 7 immediately after dosing

Part B: Maximum observed plasma concentration (Cmax) of GSK2269577 on Day 7

Timeframe: Day 7 immediately after dosing

Part A: Trough concentration (Ctau) of GSK2269577 on Day 7 and Day 15

Timeframe: Day 7 and Day 15

Part B: Trough concentration (Ctau) of GSK2269577 on Day 7 and Day 15

Timeframe: Day 7 and Day 15

Part B: Number of times rescue medication was used by participants daily, during the treatment period

Timeframe: Day 1 to Day 15

Part B: Number of participants with at least one non-serious adverse event (AE), serious adverse event (SAE), or drug-related adverse event

Timeframe: From the start of study treatment until follow-up (assessed for approximately 19 days)

Part B: Change from Baseline in counts of basophils, eosinophils, lymphocytes, monocytes, platelets, white blood cells (WBC), total neutrophils (total ANC) at the indicated time points

Timeframe: Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)

Part B: Change from Baseline in hemoglobin and mean corpuscle hemoglobin concentration (MCHC) at the indicated time points

Timeframe: Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)

Part B: Change from Baseline in counts of RBCs and reticulocytes at the indicated time points

Timeframe: Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)

Part B: Change from Baseline in hematocrit at the indicated time points

Timeframe: Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)

Part B: Change from Baseline in mean corpuscle hemoglobin (MCH) at the indicated time points

Timeframe: Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)

Part B: Change from Baseline in mean corpuscle volume (MCV) at the indicated time points

Timeframe: Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)

Part B: Change from Baseline in albumin and total protein at the indicated time points

Timeframe: Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)

Part B: Change from Baseline in alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), and gamma glutamyl transferase (GGT) at the indicated time points

Timeframe: Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)

Part B: Change from Baseline in creatinine, bilirubin, and total bilirubin at the indicated time points

Timeframe: Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)

Part B: Change from Baseline in calcium, potassium, sodium, glucose, and blood urea nitrogen (BUN) at the indicated time points

Timeframe: Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)

Part B: Number of participants meeting criteria of potential clinical importance for systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate (HR) at any visit post-Baseline

Timeframe: Day 1, Day 7, and Day 14

Part B: Number of participants with normal and abnormal (clinically significant or not clinically significant) findings in 12-lead electrocardiogram (ECG) at any visit post-Baseline

Timeframe: Day 1, Day 7, and Day 14

Part B: Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) at Screening and Follow-up

Timeframe: Screening (up to 30 days prior to Day 1) and Follow-up (approximately Day 19)

Interventions:
  • Drug: GSK2269557 100 MCG
  • Drug: GSK2269557 500 MCG
  • Drug: PLACEBO
    • Enrollment:
    64
    Primary completion date:
    2015-18-08
    Observational study model:
    Not applicable
    Time perspective:
    Not applicable
    Clinical publications:
    Cahn A1*, Hamblin JN2*, Begg M2, Wilson R1, Dunsire L1, Sriskantharajah S2, Montembault M5, Leemereise C4, Galinanes-Garcia L4, Watz H, Kirsten AM3, Fuhr R3, Hessel EM2. Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3k? inhibitor under development for the treatment of COPD. Pulm Pharmacol Ther.2017;46:69-77.
    Medical condition
    Pulmonary Disease, Chronic Obstructive
    Product
    nemiralisib
    Collaborators
    Not applicable
    Study date(s)
    July 2014 to August 2015
    Type
    Interventional
    Phase
    2

    Participation criteria

    Sex
    Female & Male
    Age
    40 - 75 years
    Accepts healthy volunteers
    No
    • The subject has a confirmed and established diagnosis of COPD, as defined by the Global Initiative for Chronic Obstructive lung Disease (GOLD) guidelines.
    • Male or female of non-child bearing potential between 40 and 75 years of age inclusive, at the time of signing the informed consent.
    • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome, asymptomatic gallstones and cholecystectomy).
    • Subjects who have a past or current medical condition or diseases that are not well controlled and, which as judged by the Investigator, may affect subject safety or influence the outcome of the study. (Note: Patients with adequately treated and well controlled concurrent medical conditions (e.g. hypertension) are permitted to be entered into the study).
    Inclusion and exclusion criteria
    Inclusion criteria:
    • The subject has a confirmed and established diagnosis of COPD, as defined by the Global Initiative for Chronic Obstructive lung Disease (GOLD) guidelines.
    • Male or female of non-child bearing potential between 40 and 75 years of age inclusive, at the time of signing the informed consent.
    • The subject has a post-bronchodilator [400 microgram (mcg) salbutamol] Maximal amount of air FEV1/FVC <0.7 and FEV1 >=40% to <=80% of predicted (Predictions should be according to the European Community of Coal and Steel (ECCS) equations).
    • Subject is a smoker or an ex-smoker with a smoking history of at least 10 pack years (pack years = (cigarettes per day smoked/20) x number of years smoked)).
    • The subject is able to produce >100 milligram (mg) of sputum at screening.
    • Body weight >=45 kilogram (kg) and body mass index (BMI) within the range 17 – 32 kg/square meter (m^2) (inclusive).
    • A female subject is eligible to participate if she is of: Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation, hysterectomy, salpingo-oophrectomy or oophrectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 milli-International units (MIU)/millilitre (mL) and estradiol < 40 picogram (pg)/mL (<147 picomole(pmol)/Liter [L]) is confirmatory]. [Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods, if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method.]; or has only same-sex partners, when this is her preferred and usual lifestyle.
    • Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods. This criterion must be followed from the time of the first dose of study medication until the follow-up visit.
    • Based on averaged QTcF values of triplicate ECGs obtained over a brief recording period (e.g. 5 minutes): QTcF <450 millisecond (msec); or QTcF<480 msec in subjects with right bundle branch block.
    • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
    • A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included if the investigator [in consultation with the Glaxosmithkline (GSK) medical monitor if required] documents that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
    Exclusion criteria:
    • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome, asymptomatic gallstones and cholecystectomy).
    • Subjects who have a past or current medical condition or diseases that are not well controlled and, which as judged by the Investigator, may affect subject safety or influence the outcome of the study. (Note: Patients with adequately treated and well controlled concurrent medical conditions (e.g. hypertension) are permitted to be entered into the study).
    • Subject has a diagnosis of active tuberculosis, lung cancer, clinically overt bronchiectasis, pulmonary fibrosis, asthma or any other respiratory condition that might, in the opinion of the Investigator, compromise the safety of the subject or affect the interpretation of the results.
    • History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >28 units for males or >21 units for females. One unit is equivalent to 8 gram of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
    • History of sensitivity to any of the study medications, or components (such as lactose) thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
    • A positive test for Human immunodeficiency virus (HIV) antibody
    • tested according to local policies.
    • The subject has a positive pre-study drug/alcohol screen. A minimum list of drugs that will be screened for include cannabinoids, amphetamines, barbiturates, cocaine and opiates. The detection of drugs (e.g. benzodiazepines, opiates) taken for a legitimate medical purpose would not necessarily be an exclusion to study participation. The detection of alcohol would not be an exclusion at screening but would need to be negative pre-dose and during the study.
    • A positive pre-study Hepatitis B surface antigen (HBs-Ag) or positive total hepatitis B core antibody (anti-HBc IgM) or positive Hepatitis C antibody result within 3 months of screening.
    • Pregnant females as determined by positive urine human chorionic gonadotropin (hCG) test at screening or prior to dosing.
    • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
    • Lactating females.
    • The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
    • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
    • Subject has poorly controlled or unstable COPD, defined as the occurrence of any of the following: Either: acute worsening of COPD (an exacerbation) that is managed by the subject at home requiring treatment with corticosteroids and/or antibiotics in the 4 weeks prior to the screening visit; or more than two exacerbations in the previous 2 months prior to the screening visit that required a course of oral corticosteroids and/or antibiotics, or for which the subject was hospitalised.
    • Subject has had a respiratory tract infection treated with antibiotics in the 4 weeks prior to first dose.
    • Subject requires regular treatment with oral corticosteroids or has received oral or parenteral corticosteroids within 4 weeks of screening.
    • Vulnerable subject (e.g., person kept in detention).
    • The subject is not able to understand and communicate in German or native language.

    Trial location(s)

    Location
    Status
    Contact us
    Contact us
    Location
    GSK Investigational Site
    Grosshansdorf, Schleswig-Holstein, Germany, 22927
    Status
    Study Complete
    Contact us
    Location
    GSK Investigational Site
    Berlin, Berlin, Germany, 14050
    Status
    Study Complete
    Contact us

    Study documents

    Scientific result summary
    Available language(s): English
    Download document(s)
    Protocol
    Available language(s): English
    Download document(s)

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Results posted on ClinicalTrials.gov

    Recruitment status
    Study complete
    Actual primary completion date
    2015-18-08
    Actual study completion date
    2015-18-08

    Plain language summaries

    Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

    Additional information about the trial

    Participate in clinical trial
    Additional information
    IPD for this study will be made available via the Clinical Study Data Request site.
    Click here
    Access to clinical trial data by researchers
    Visit website